HK1250011A1 - 具有蛋白酶可切割接头的肽构建体 - Google Patents

具有蛋白酶可切割接头的肽构建体 Download PDF

Info

Publication number
HK1250011A1
HK1250011A1 HK18109446.1A HK18109446A HK1250011A1 HK 1250011 A1 HK1250011 A1 HK 1250011A1 HK 18109446 A HK18109446 A HK 18109446A HK 1250011 A1 HK1250011 A1 HK 1250011A1
Authority
HK
Hong Kong
Prior art keywords
protease
cleavable linker
peptide construct
labile
peptide linker
Prior art date
Application number
HK18109446.1A
Other languages
English (en)
Chinese (zh)
Inventor
Scott Crowe
Mike West
Kevin Roberts
Original Assignee
Sorriso Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorriso Pharmaceuticals, Inc. filed Critical Sorriso Pharmaceuticals, Inc.
Publication of HK1250011A1 publication Critical patent/HK1250011A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HK18109446.1A 2015-03-31 2016-03-31 具有蛋白酶可切割接头的肽构建体 HK1250011A1 (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP15162115 2015-03-31
EP15162112.5 2015-03-31
EP15162114 2015-03-31
EP15162114.1 2015-03-31
EP15162115.8 2015-03-31
EP15162112 2015-03-31
EP16152320 2016-01-21
EP16152320.4 2016-01-21
PCT/EP2016/057022 WO2016156466A1 (en) 2015-03-31 2016-03-31 Peptide construct having a protease-cleavable linker

Publications (1)

Publication Number Publication Date
HK1250011A1 true HK1250011A1 (zh) 2018-11-23

Family

ID=55661404

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18109446.1A HK1250011A1 (zh) 2015-03-31 2016-03-31 具有蛋白酶可切割接头的肽构建体

Country Status (11)

Country Link
US (3) US20180037639A1 (cg-RX-API-DMAC7.html)
EP (1) EP3277317A1 (cg-RX-API-DMAC7.html)
JP (2) JP7064670B2 (cg-RX-API-DMAC7.html)
KR (1) KR102789821B1 (cg-RX-API-DMAC7.html)
CN (1) CN107427577A (cg-RX-API-DMAC7.html)
AU (2) AU2016239949A1 (cg-RX-API-DMAC7.html)
CA (1) CA2981098A1 (cg-RX-API-DMAC7.html)
HK (1) HK1250011A1 (cg-RX-API-DMAC7.html)
IL (1) IL254589B2 (cg-RX-API-DMAC7.html)
SG (1) SG11201706840WA (cg-RX-API-DMAC7.html)
WO (1) WO2016156466A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9134766B2 (en) 2009-10-20 2015-09-15 Hewlett-Packard Development Company, L.P. Keyboard hold down mechanism
AU2016239949A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Peptide construct having a protease-cleavable linker
EP3277719B1 (en) 2015-03-31 2022-03-16 Sorriso Pharmaceuticals, Inc. Polypeptides
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
GB201709222D0 (en) * 2017-06-09 2017-07-26 Univ Manchester C3b Inactivating Polypeptide
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
WO2020144164A1 (en) 2019-01-07 2020-07-16 Bactolife Aps Pathogen binding proteins
WO2020191361A2 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicles for vaccine delivery
WO2020215010A1 (en) 2019-04-17 2020-10-22 Codiak Biosciences, Inc. Compositions of exosomes and aav
CA3144566A1 (en) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Polypeptides
JP7692844B2 (ja) 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ,インク. ポリペプチド
US12570736B2 (en) 2019-06-21 2026-03-10 Sorriso Pharmaceuticals, Inc. Compositions
US20220251200A1 (en) 2019-07-03 2022-08-11 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3300077A (en) 1965-02-18 1967-01-24 Clinch Tite Corp Pallet enclosure
EP0486526B2 (en) 1989-08-07 2001-03-07 Peptech Limited Tumour necrosis factor binding ligands
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU664561B2 (en) 1991-06-21 1995-11-23 University Of Cincinnati, The Orally administrable therapeutic proteins and method of making
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US5512459A (en) * 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
US5780028A (en) 1993-09-20 1998-07-14 Anadis Ltd. Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition
EP0739981A1 (en) * 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
EP0954978B1 (en) 1998-03-12 2011-11-30 VHsquared Limited New products comprising inactivated yeasts or moulds provided with active antibodies
ES2299244T3 (es) * 1998-05-13 2008-05-16 Domantis Limited Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
AUPP702498A0 (en) 1998-11-09 1998-12-03 Silverbrook Research Pty Ltd Image creation method and apparatus (ART77)
GB9909301D0 (en) 1999-04-22 1999-06-16 Kci Medical Ltd Wound treatment apparatus employing reduced pressure
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
PL204737B1 (pl) 2000-12-13 2010-02-26 Unilever Nv Sposób wytwarzania heterologicznego białka przez grzyby
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US9770517B2 (en) * 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20040131614A1 (en) 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20060034833A1 (en) 2002-11-08 2006-02-16 Els Beirnaert Single domain antibodies directed against interferron-gamma and uses therefor
CA2817265A1 (en) 2003-04-11 2004-10-28 Medimmune, Llc Recombinant il-9 antibodies and uses thereof
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US8007827B2 (en) 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療TNFα相關失調症之多重可變劑量療法
ATE474118T1 (de) 2004-07-14 2010-07-15 Blum Gmbh Julius Stellmechanismus für einen schwenkbar gelagerten stellarm
MX2007006086A (es) 2004-11-25 2007-07-11 Unilever Nv Anticuerpos de cadena pesada y de dominio.
CA2592015A1 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
US7234616B2 (en) 2004-12-27 2007-06-26 Bel-Art Products, Inc. Friction arrangement for hosiery donning aid
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US20070042399A1 (en) * 2005-06-23 2007-02-22 Imperial College Innovations Limited Biological materials and uses thereof
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
JP5049973B2 (ja) 2005-08-30 2012-10-17 アクトジェニックス・エヌブイ 慢性全腸炎の治療のための、抗−TNFα産生乳酸菌
ME02705B (me) 2005-08-31 2017-10-20 Merck Sharp & Dohme Inženjerisana anti-il-23 antitela
WO2007048022A2 (en) * 2005-10-21 2007-04-26 Alexion Pharmaceuticals, Inc. Antibody-polypeptide fusion proteins and methods for producing and using same
US20090286962A1 (en) 2005-12-20 2009-11-19 Woolven Benjamin P Chimeric antibodies with part new world primate binding regions
WO2007104529A2 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
US20080026820A1 (en) 2006-07-05 2008-01-31 Aruze Gaming America, Inc. Slot machine and playing method thereof
US20080031770A1 (en) 2006-08-02 2008-02-07 Douglas Heselton Apparatus and method for using ozone as a disinfectant
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン.ヴェー. Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
EP2081555A2 (en) 2006-09-12 2009-07-29 Cosmo Technologies Ltd. Pharmaceutical compositions for the oral or rectal administration of protein substances
WO2008039761A2 (en) 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
EP2071927A2 (en) * 2006-09-28 2009-06-24 Illumina, Inc. Compositions and methods for nucleotide sequencing
WO2008049897A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
TW200823720A (en) 2006-11-27 2008-06-01 Asustek Comp Inc Portable computer
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
WO2008075356A2 (en) 2006-12-19 2008-06-26 Shay Bushinsky Interactive broadcast system and method
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
TWI317699B (en) 2006-12-25 2009-12-01 Ind Tech Res Inst Device and method for removing residues
US7459949B2 (en) 2007-01-30 2008-12-02 Mosaid Technologies Incorporated Phase detector circuit and method therefor
US20160031971A9 (en) 2007-02-20 2016-02-04 Tufts University Methods and compositions with a recombinant neutralizing binding protein for treating toxin exposure
PT2079445E (pt) 2007-02-20 2016-02-29 Allergan Pharmaceuticals Internat Ltd Composições de enzimas digestivas estáveis
CN101663319A (zh) 2007-02-21 2010-03-03 埃博灵克斯股份有限公司 针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病
EP2061440A2 (en) 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
US7807168B2 (en) 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2008144753A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2696263C (en) * 2007-08-15 2017-06-13 Bing Liu Monospecific and multispecific antibodies and method of use
TWM333751U (en) 2007-09-07 2008-06-01 Jarllytec Co Ltd Supporting-type pivot structure
US20100239682A1 (en) 2007-09-17 2010-09-23 Antoine Andremont Colonic delivery of antimicrobial agents
WO2009046168A1 (en) 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
DK3354276T3 (da) 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
EP2238093A1 (en) 2008-02-07 2010-10-13 Total Petrochemicals Research Feluy Dehydration of alcohols in the presence of an inert component
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
LT2285408T (lt) 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
ES2425977T3 (es) 2008-08-14 2013-10-18 Nippon Paper Chemicals Co., Ltd. Composición de resina dispersante, y composición de pintura, composición de tinta, composición adhesiva y composición de imprimación que la contienen
GB0815264D0 (en) 2008-08-21 2008-09-24 Syntaxin Ltd Non-cytotoxic proteins
CN102215875B (zh) * 2008-10-16 2014-08-06 凯瑟琳·科根·法瑞纳斯 持续药物递送系统
PL2346927T3 (pl) 2008-10-17 2014-12-31 Maxbiogas Gmbh Sposób fermentacji biomasy zawierającej ligninę wraz z celulozą i/lub hemicelulozą
RU2481824C2 (ru) 2008-10-29 2013-05-20 Аблинкс Н.В Препараты однодоменных антигенсвязывающих молекул
CN105646643A (zh) 2008-10-29 2016-06-08 阿布林克斯公司 单域抗原结合性分子的纯化方法
US8697654B2 (en) * 2008-12-18 2014-04-15 E I Du Pont De Nemours And Company Peptide linkers for effective multivalent peptide binding
WO2010085643A1 (en) 2009-01-22 2010-07-29 University Of Miami Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders
MX2011010681A (es) 2009-04-10 2012-01-20 Ablynx Nv Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
CN101964403A (zh) 2009-07-23 2011-02-02 比克国际(天津)有限公司 一种电池组的封装方法及电池组
CN102090373A (zh) 2009-12-11 2011-06-15 中国医学科学院血液病医院(血液学研究所) 模拟人克隆氏病的小鼠结肠炎模型及其制备方法和用途
CL2010000019A1 (es) 2010-01-11 2010-06-11 Univ Chile Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion.
CA2787070A1 (en) 2010-01-28 2011-08-04 Ian Kirby Cd127 binding proteins
US20130012916A1 (en) 2010-02-11 2013-01-10 Glide Pharmaceutical Technologies Limited Delivery of immunoglobulin variable domains and constructs thereof
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
CN105168174B (zh) 2010-03-10 2019-01-08 拉尼医疗有限公司 用于利用可吞咽式药剂递送装置递送到肠道内腔中的治疗剂制剂
WO2011139629A2 (en) * 2010-04-26 2011-11-10 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
AU2011247612A1 (en) 2010-04-30 2012-12-06 Ablynx Nv Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine IL-23
WO2011135040A1 (en) * 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
WO2011139269A1 (en) 2010-05-04 2011-11-10 Johnson Controls Technology Company Variable speed drive
AU2011277983C1 (en) 2010-07-16 2016-09-29 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
CA2815888C (en) 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
US9460623B2 (en) 2010-11-22 2016-10-04 International Business Machines Corporation Parking management
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
US8566574B2 (en) 2010-12-09 2013-10-22 International Business Machines Corporation Secure encrypted boot with simplified firmware update
US8634563B2 (en) 2010-12-17 2014-01-21 Microsoft Corporation Attribute based encryption using lattices
WO2012130872A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
MX2013011366A (es) 2011-03-30 2014-05-12 Chugai Pharmaceutical Co Ltd Retencion de las moleculas de union al antigeno en el plasma sanguineo y metodo para modificar la inmunogenicidad.
AU2012237287B2 (en) 2011-03-30 2016-09-08 Ablynx Nv Methods of treating immune disorders with single domain antibodies against TNF-alpha
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
KR20140084201A (ko) * 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
EP2583980A1 (en) 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
GB2504139B (en) 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
DE102011121238A1 (de) 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
DE102011121237A1 (de) 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
CN104169304A (zh) 2011-12-20 2014-11-26 阿达拉塔合伙有限公司 作为pcsk9抑制剂的单域抗体
US8874636B2 (en) 2012-01-03 2014-10-28 Teletech Holdings, Inc. Method for providing support services using consumer selected specialist and specialist ratings
PL2831111T3 (pl) * 2012-03-30 2019-09-30 Boehringer Ingelheim International Gmbh Cząsteczki wiążące Ang2
SI2849723T1 (sl) 2012-05-18 2018-09-28 Genentech, Inc. Formulacije z visoko koncentracijo monoklonskih protiteles
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
WO2014004746A2 (en) 2012-06-26 2014-01-03 Harvard Bioscience, Inc. Methods and compositions for promoting the structural integrity of scaffolds for tissue engineering
JP2014026709A (ja) 2012-07-30 2014-02-06 International Business Maschines Corporation ライブラリ・ストリング間でのカートリッジの移動方法、システム、及びプログラム
NZ704771A (en) 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
EP2887960A2 (en) 2012-08-21 2015-07-01 Glaxo Group Limited Compositions comprising a single variable domain and camostat mesylate (cm)
MX2015004436A (es) 2012-10-09 2015-06-24 Biogen Idec Inc Tratamientos conjuntos y usos para tratar trastornos desmielinizantes.
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
US20140186365A1 (en) * 2013-01-03 2014-07-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn
SG11201507026WA (en) 2013-02-06 2015-10-29 Anthrogenesis Corp Modified t lymphocytes having improved specificity
AU2014229282B2 (en) 2013-03-15 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Low concentration antibody formulations
WO2015009996A1 (en) 2013-07-19 2015-01-22 The Trustees Of The University Of Pennsylvania Compositions and methods for treating eosinophilic esophagitis
US20150058173A1 (en) 2013-08-20 2015-02-26 Sears Brands, Llc Sales promotion using product comparison
US20160228371A1 (en) 2013-10-18 2016-08-11 Abbvie Inc. Stable solid units and methods of making the same
CA2924520C (en) 2013-11-01 2023-09-26 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
WO2015100409A2 (en) 2013-12-26 2015-07-02 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
US10233238B2 (en) 2014-03-26 2019-03-19 Cell Medica Switzerland Ag TNF alpha antibody or fragment thereof and methods of use
WO2015176031A2 (en) 2014-05-15 2015-11-19 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
CA2959629C (en) 2014-09-03 2023-10-31 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
PL3590962T3 (pl) 2014-10-23 2022-01-31 Singh Molecular Medicine, Llc Przeciwciała jednodomenowe przeciwko antygenom wewnątrzkomórkowym
US20170360929A1 (en) 2014-12-23 2017-12-21 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
US20170260266A1 (en) 2015-03-11 2017-09-14 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
EP3277706A1 (en) 2015-03-31 2018-02-07 VHsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
WO2016156474A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a
EP3277719B1 (en) 2015-03-31 2022-03-16 Sorriso Pharmaceuticals, Inc. Polypeptides
AU2016239949A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Peptide construct having a protease-cleavable linker
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
EP3405491A1 (en) 2016-01-21 2018-11-28 VHsquared Limited Polypeptides
EP3435982A1 (en) 2016-03-31 2019-02-06 VHsquared Limited Compositions
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
CN110392695B (zh) 2016-12-09 2021-02-02 Ose免疫疗法 针对cd127的抗体和多肽
EP3635410A4 (en) 2017-06-04 2021-03-10 Rappaport Family Institute for Research in the Medical Sciences PROCEDURE FOR PREDICTING PERSONALIZED RESPONSE TO CANCER TREATMENT USING IMMUNE CHECKPOINT INHIBITORS AND KITS
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
JP7692844B2 (ja) * 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ,インク. ポリペプチド
US12570736B2 (en) * 2019-06-21 2026-03-10 Sorriso Pharmaceuticals, Inc. Compositions
CA3144566A1 (en) * 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Polypeptides

Also Published As

Publication number Publication date
KR20170132154A (ko) 2017-12-01
AU2022201410A1 (en) 2022-03-24
IL254589B2 (en) 2023-11-01
JP2018515596A (ja) 2018-06-14
AU2016239949A1 (en) 2017-09-07
US12234279B2 (en) 2025-02-25
SG11201706840WA (en) 2017-09-28
KR102789821B1 (ko) 2025-04-02
EP3277317A1 (en) 2018-02-07
JP2022081634A (ja) 2022-05-31
CA2981098A1 (en) 2016-10-06
IL254589A0 (en) 2017-11-30
US20180037639A1 (en) 2018-02-08
WO2016156466A1 (en) 2016-10-06
US20210198345A1 (en) 2021-07-01
US20250388655A1 (en) 2025-12-25
AU2022201410B2 (en) 2025-04-10
JP7064670B2 (ja) 2022-05-11
CN107427577A (zh) 2017-12-01
IL254589B1 (en) 2023-07-01

Similar Documents

Publication Publication Date Title
AU2015274647C1 (en) Protease-cleavage resistant, Shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
AU2019247434A1 (en) Camptothecin Peptide Conjugates
EP3309177A4 (en) Pdl-1 antibody, pharmaceutical composition thereof, and uses thereof
ZA201705923B (en) Drug conjugates comprising antibodies against claudin 18.2
WO2015179691A3 (en) Cell penetrating peptides and methods of making and using thereof
WO2018064119A8 (en) CALPAIN MODULATORS AND THEIR THERAPEUTIC USES
WO2016210365A3 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
EP4600372A3 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2015051030A8 (en) Stabilized polypeptides and uses thereof
WO2015048348A3 (en) Compositions and formulations for increasing renal function and treatment and prevention of renal diseases, and methods of production and use thereof
WO2015057876A8 (en) Drug-conjugates with a targeting molecule and two different drugs
ZA201400610B (en) Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
WO2018136620A3 (en) Endosomal cleavable linkers
WO2018098282A3 (en) Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
WO2017015634A3 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
MY197825A (en) Novel peptide
EP3676250A4 (en) PEPTIDE CONJUGATES, CONJUGATION METHODS AND USES THEREOF
USD847266S1 (en) Adinkra card game
WO2018132696A3 (en) Stomach acid-stable and mucin-binding protein-polymer conjugates
NZ629130A (en) Tfpi inhibitors and methods of use
EP3653063A4 (en) PEPTIDE
WO2014179184A8 (en) Compositions for inducing immune tolerance to coagulation factor proteins
MX2017008406A (es) Conjugados de aminoacidos y peptidos y sus usos.
EP3582810A4 (en) Ss-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES
LT3626729T (lt) Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį